Business
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2022 financial results on Wednesday, March 8, 2023. Mirum will also host a conference call to discuss the fourth quarter and year-end 2022 financial results and recent corporate progress.\n\nConference call details:\nWednesday, March 8, 2023\n4:30 p.m. ET / 1:30 p.m. PT\n\nDial-in:\nU.S./Toll-Free: 1 833 927 1758\nInternational: 1 929 526 1599\nPasscode: 596100\n\nYou may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.\n\nAbout Mirum Pharmaceuticals, Inc.\n\nMirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older, and in Europe for the same indication in patients two months of age and older.\n\nMirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.\n\nMirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.\n\nFollow Mirum on Twitter, Facebook, LinkedIn and Instagram.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230301005320/en/\n\nInvestor Contacts:\nAndrew McKibben\[email protected]\n\nSam Martin\nArgot Partners\[email protected]\n\nMedia Contact:\nErin Murphy\[email protected]\n\nSource: Mirum Pharmaceuticals, Inc.","length":5992,"tagName":"div"}]